Reference
- Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37(7):2291–6
- Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353(9171):2195–9
- Baxter J, Mayers D, Wentworth D, et al. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretoviral resistance testing (GART) in patients failing antiretroviral treatment. (Abstr LB8) Proceedings, 6th Conference on Retroviruses and Opportunistic Infections. Chicago: 1999 Jan 31-Feb 4-Available at: http://www.retroconference.org/99. Accessed Feb 23, 2000
- Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269(5224):696–9
- Miller V, Hertogs K, Sabin C, et al. Phenotypic susceptibility to adefovir dipivoxil in clinical samples with defined RT genotypic resistance patterns. (Abstr 433) Proceedings, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 Sep 26–9. Available at: http://www.medscape.com. Accessed Feb 23, 2000
- Baker D, Paul M, Jefferey S, et al. Efavirenz response in NNRTI-experienced patients: results from Sustiva expanded access program. (Abstr 2200) Proceedings, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999 Sep 26–9. Available at: http://www.medscape.com. Accessed Feb 23, 2000
- Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996; 2(7):760–6
- Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374(6522): 569–71
- Zolopa AR, Shafer RW, Warford A, et al. HIV-1' genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131 (11):813–21
- Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotype drug susceptibility with virologie outcome. J Infect Dis 1999; 179(6): 1375–81
- Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13(6):35–43F